Caredx (CDNA) reported $380M in revenue for fiscal 2025, +13.8% year on year. That ranks #2378 by revenue among 2853 SEC filers and #233 in Healthcare. It posted a net loss of −$21.4M for the same year. Revenue has grown 25.2% a year on average since 2012 ($20.5M then). The fiscal 2025 balance sheet shows $413M in total assets, $65.4M in cash and $0 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $380M | +13.8% | FY20252025-12-31 |
| Gross profitGrossProfit | $81.6M | +87.3% | FY20192019-12-31 |
| Operating incomeOperatingIncomeLoss | −$30.8M | −$71.5M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$21.4M | −$73.9M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $42.0M | +10.5% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $2.0M | +994.1% | FY20182018-12-31 |
| Total assetsAssets | $413M | −15.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $303M | −19.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $65.4M | −43.0% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $0 | $0 | FY20202020-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $118M | $2.8M | Open → |
| Q2 20262026-06-30 | $132M | $111M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Caredx, Inc.
- Ticker
- CDNA
- Exchange
- Nasdaq
- SIC classification
- Services-Medical Laboratories (8071)
- Fiscal year end
- 12-31
- CIK
- 0001217234
Filings
- 10-QJul 30, 2026Open filing →
- 10-QApr 28, 2026Open filing →
- 10-KFeb 25, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Krystal BiotechKRYS | $389M | $205M |
| Sinovac BiotechSVA | $386M | −$199M |
| Sonida Senior LivingSNDA | $381M | −$72.5M |
| CaredxCDNA | $380M | −$21.4M |
| Twist BioscienceTWST | $377M | −$77.7M |
| Pharming GroupPHAR | $376M | $2.9M |
| Arcutis BiotherapeuticsARQT | $376M | −$16.1M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Caredx — Key figures |url=https://companiesranked.com/en/company/caredx |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Caredx — Key figures. CompaniesRanked. https://companiesranked.com/en/company/caredxBibTeX
@misc{companiesranked-en-company-caredx-2026,
author = {{CompaniesRanked}},
title = {{Caredx — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/caredx}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001217234-26-000018 · February 25, 2026
{{cite web |title=Caredx — Key figures — 10-K (0001217234-26-000018) |url=https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.